402 related articles for article (PubMed ID: 17102073)
1. Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET).
Whitman HH; Fishman EK; Oberg K; Wildman JM; Long AL
Ann N Y Acad Sci; 2006 Aug; 1073():59-78. PubMed ID: 17102073
[TBL] [Abstract][Full Text] [Related]
2. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
3. MEN 1 and 2: the role of diagnostic imaging.
Gollini P; Cataldi A; Fava C
Radiol Med; 2004; 107(1-2):78-87. PubMed ID: 15031699
[TBL] [Abstract][Full Text] [Related]
4. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
5. A case of pheochromocytoma with negative MIBG scintigraphy, PET-CT and genetic tests (VHL included) and a rare case of post-operative erectile dysfunction.
Defeudis G; Fioriti E; Palermo A; Tuccinardi D; Minucci A; Capoluongo E; Pozzilli P; Manfrini S
Hormones (Athens); 2018 Jun; 17(2):279-284. PubMed ID: 29860716
[TBL] [Abstract][Full Text] [Related]
6. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO).
Timmers HJ; Eisenhofer G; Carrasquillo JA; Chen CC; Whatley M; Ling A; Adams KT; Pacak K
Clin Endocrinol (Oxf); 2009 Jul; 71(1):11-7. PubMed ID: 19138315
[TBL] [Abstract][Full Text] [Related]
7. Pheochromocytoma: diagnosis and management update.
Manger WM; Eisenhofer G
Curr Hypertens Rep; 2004 Dec; 6(6):477-84. PubMed ID: 15527694
[TBL] [Abstract][Full Text] [Related]
8. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
9. [Adrenal incidentaloma: a dopamine-secreting pheochromocytoma with an atypical clinical picture. A case report and review of the literature].
Bartolacci M; Bartolacci S; Leombruni E; Annunziata A; Di Rienzo M; Picardi N
Ann Ital Chir; 1998; 69(6):805-14. PubMed ID: 10213955
[TBL] [Abstract][Full Text] [Related]
10. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome.
Pacak K; Eisenhofer G; Ilias I
Hormones (Athens); 2009; 8(2):111-6. PubMed ID: 19570738
[TBL] [Abstract][Full Text] [Related]
12. Pheochromocytomas and secreting paragangliomas.
Plouin PF; Gimenez-Roqueplo AP
Orphanet J Rare Dis; 2006 Dec; 1():49. PubMed ID: 17156452
[TBL] [Abstract][Full Text] [Related]
13. Anatomical and functional imaging of metastatic pheochromocytoma.
Ilias I; Pacak K
Ann N Y Acad Sci; 2004 Jun; 1018():495-504. PubMed ID: 15240407
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome.
Ilias I; Pacak K
Endocr Regul; 2009 Apr; 43(2):89-93. PubMed ID: 19856714
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and localization of pheochromocytoma.
Goldstein DS; Eisenhofer G; Flynn JA; Wand G; Pacak K
Hypertension; 2004 May; 43(5):907-10. PubMed ID: 15023935
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging.
Nakatani T; Hayama T; Uchida J; Nakamura K; Takemoto Y; Sugimura K
Oncol Rep; 2002; 9(6):1225-7. PubMed ID: 12375024
[TBL] [Abstract][Full Text] [Related]
17. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
van der Harst E; de Herder WW; Bruining HA; Bonjer HJ; de Krijger RR; Lamberts SW; van de Meiracker AH; Boomsma F; Stijnen T; Krenning EP; Bosman FT; Kwekkeboom DJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):685-93. PubMed ID: 11158032
[TBL] [Abstract][Full Text] [Related]
18. [Personal experience in diagnosis and localization of pheochromocytoma].
Andjelković Z; Tavcar I
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():14-9. PubMed ID: 12584992
[TBL] [Abstract][Full Text] [Related]
19. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma.
Ilias I; Yu J; Carrasquillo JA; Chen CC; Eisenhofer G; Whatley M; McElroy B; Pacak K
J Clin Endocrinol Metab; 2003 Sep; 88(9):4083-7. PubMed ID: 12970267
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic management of benign and malignant pheochromocytoma.
Scholz T; Schulz C; Klose S; Lehnert H
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):155-9. PubMed ID: 17427102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
